Fosphenytoin Sodium Injection, USP, 500 mg PE/10 mL (50 mg PE/mL), (PE= phenytoin sodium equivale...
FDA Drug Recall #D-1429-2014 — Class II — May 2, 2014
Recall Summary
| Recall Number | D-1429-2014 |
| Classification | Class II — Moderate risk |
| Date Initiated | May 2, 2014 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Fresenius Kabi USA, LLC |
| Location | Melrose Park, IL |
| Product Type | Drugs |
| Quantity | 728,880 vials |
Product Description
Fosphenytoin Sodium Injection, USP, 500 mg PE/10 mL (50 mg PE/mL), (PE= phenytoin sodium equivalents) 10 mL Single Use Vial, Rx only, Manufactured for APP Fresenius Kabi USA, LLC Lake Zurich, IL 60047, NDC 63323-403-10
Reason for Recall
Presence of Particular Matter: Potential glass delamination and consistent with glass particulates observed in sample vials.
Distribution Pattern
Nationwide and Puerto Rico
Lot / Code Information
Lot # 6003854; 04/14 6003855; 04/14 6004011; 05/14 6003961; 05/14 6004091; 06/14 6004092; 06/14 6004553; 08/14 6004554; 08/14 6004588; 09/14 6004589; 09/14 6005201; 12/14 6005202; 12/14 6005293; 12/14 6005294; 12/14 6005545; 02/15 6005546; 02/15 6005831; 03/15 6005832; 03/15 6005973; 04/15 6005974; 04/15 6006035; 05/15 6006036; 05/15 6006037; 05/15 6006174; 05/15 6006175; 05/15 6006176; 06/15 6006449; 07/15 6006450; 07/15 6006451; 07/15 6007168; 11/15
Other Recalls from Fresenius Kabi USA, LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0182-2026 | Class I | Famotidine Injection, USP, 20 mg per 2 mL (10 m... | Nov 6, 2025 |
| D-0127-2023 | Class II | Sensorcaine (Bupivacaine HCl and Epinephrine In... | Nov 22, 2022 |
| D-0128-2023 | Class II | Sensorcaine (Bupivacaine HCl and Epinephrine In... | Nov 22, 2022 |
| D-0129-2023 | Class II | Sensorcaine-MPF (Bupivacaine HCl and Epinephrin... | Nov 22, 2022 |
| D-0750-2022 | Class I | Sodium Acetate Injection, USP, 400 mEq / 100 mL... | Mar 4, 2022 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.